Ola E. Dahl
Innlandet Hospital Trust
105 Papers
1.1K Citations
Ola E. Dahl is an academic researcher from Innlandet Hospital Trust. The author has contributed to research in topics: Dabigatran & Medicine. The author has an hindex of 41, co-authored 105 publications.
Chat about Author
Papers
Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Yngve Falck-Ytter,Charles W. Francis,Norman A. Johanson,Catherine Curley,Ola E. Dahl,Sam Schulman,Thomas L. Ortel,Stephen G. Pauker,Clifford W. Colwell +8 more
TL;DR: In this article, the authors focus on optimal prophylaxis to reduce postoperative pulmonary embolism and DVT following major orthopedic surgery, and suggest the use of low-molecular-weight heparin in preference to the other agents we have recommended as alternatives.
2.7K
Prevention of VTE in Orthopedic Surgery Patients
Yngve Falck-Ytter,Charles W. Francis,Norman A. Johanson,Catherine Curley,Ola E. Dahl,Sam Schulman,Thomas L. Ortel,Stephen G. Pauker,Clifford W. Colwell +8 more
TL;DR: Optimal strategies for thromboprophylaxis after major orthopedic surgery include pharmacologic and mechanical approaches.
2K
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C Niek van Dijk,Simon P. Frostick,Martin H. Prins,Rohan Hettiarachchi,Stefan Hantel,Janet Schnee,Harry R. Büller +10 more
TL;DR: Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile.
1.1K
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar,Benjamin Brenner,Ola E. Dahl,Bengt I. Eriksson,Patrick Mouret,James Muntz,Andrea G. Soglian,Akos F. Pap,Frank Misselwitz,Sylvia Haas +9 more
TL;DR: Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty.
1.1K
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Bengt I. Eriksson,Ola E. Dahl,Nadia Rosencher,Andreas A. Kurth,C. N. Van Dijk,Simon P. Frostick,Peter Kälebo,Anita Vedel Christiansen,Stefan Hantel,Rohan Hettiarachchi,Janet Schnee,Harry R. Büller +11 more
TL;DR: Dabigatran etexilate (220 mg or 150‰mg) was at least as effective as enoxaparin and had a similar safety profile for prevention of VTE after total knee replacement surgery.
1K